The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Arrowhead Pharmaceuticals, Inc. shares have underperformed despite a lucrative $1.1bn+ licensing deal with Sarepta, providing significant upfront and milestone payments. The Sarepta partnership ...

By Connor Hart Shares of Sarepta Therapeutics fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market.

Arrowhead expects to receive a $500 million upfront payment in the next 10 days and has already received $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per ...

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta’s purchase of Arrowhead common stock at $27.25 per share. Over the next five years, Arrowhead is set ...

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta's purchase of Arrowhead common stock at $27.25 per share.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ ...

Upon closing, Arrowhead receives a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share. Arrowhead will also receive ...

Upon closing, Sarepta will provide Arrowhead with $825 million, consisting of $500 million cash and $325 million as an equity investment. Arrowhead will also receive $250 million paid out over ...